While low- and middle-income countries remain desperate for a COVID-19 vaccine, the United States has entered a dangerous new phase of the pandemic, where antivaccine forces are exporting their antiscience beliefs to other countries, according to a keynote speaker at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
The American Academy of Ophthalmology conference is scheduled to take place in-person and online from November 12-15, 2021.
Carina Venter, PhD, RD, allergy specialist dietitian and associate professor in pediatric allergy and immunology at Children's Hospital Colorado and the University of Colorado, discusses the gut microbiome’s complex relationship with our immune system and diet diversity’s potential role in allergic disease and food allergy–related outcomes.
An afternoon session at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting focused on key updates in pediatric anaphylaxis from the past year as seen in published data.
Misinformation is not supported by the data on the science of vaccination, agreed experts during “Combating Misinformation in Science,” which took place at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology annual meeting program chair, discusses the importance of distinguishing between non–immunoglobulin E (IgE)– and IgE-mediated food allergies, as well as remaining up to date on guidance for eosinophilic esophagitis (EoE).
Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses antivaccination sentiment and how to overcome it to find an optimal solution to end the COVID-19 pandemic.
With new and expected future options for treating atopic dermatitis (AD), including an injectable biologic and an oral small molecule inhibitor, which is preferred and which makes the most sense for patients?
In 2017, guidelines about when to feed peanuts to infants changed to recommend early feeding by 4 to 6 months of age depending on 3 risk levels, but these allergy prevention strategies are still not widespread, according to Ruchi Gupta, MD, MPH, professor of pediatrics and medicine, Northwestern Feinberg School of Medicine, who discussed the topic at the 2021 ACAAI Annual Scientific Meeting.
Two experts explore disparities in atopic dermatitis by age, skin color, and ethnicity.
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses the connection between health literacy and lack of trust in science and also addresses allergy concerns toward COVID-19 vaccines.
The 2021 ACAAI Annual Scientific Meeting, taking place virtually and in person in New Orleans, kicks off on Thursday, November 4, by focusing on dermatology and atopic dermatitis and concludes on Monday, November 8, with a final plenary session that addresses updates to several treatment guidelines.
Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting program chair, discusses how this year’s conference content will demonstrate the joint themes of innovation and diversity, as well as what exciting developments presenters and attendees alike should watch for.
Erika Glenn, Division Head of Sales, Care Management, CVS Health, addressed some of the latest innovations in predictive modeling and data analytics being leveraged by her organization in the management of patients with chronic conditions at the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.
A panel at Asembia 2021 Specialty Pharmacy Summit in Las Vegas addressed challenges in the treatment journey of patients with rare diseases, efforts to improve access to gene therapies, and cost and value considerations for stakeholders.
Oncology drugs are a huge driver of cost, but there’s a lot of innovation happening in the space to improve care and outcomes for patients, said Michelle Booth, PharmD, director of specialty clinical solutions at Magellan Rx Management.
Panelists from a session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas discussed considerations for manufacturers, specialty pharmacies, and payers entering the rare disease and gene therapy market.
The state of value-based contracting in specialty pharmacy was addressed in a panel discussion at Asembia 2021 Specialty Pharmacy Summit in Las Vegas, with speakers touching on the essentials of such agreements, how to optimally integrate them, and future considerations for the pharmaceutical marketplace.
Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
Panelists of the opening session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas address emerging shifts in specialty pharmacy, its impact on the health care system, and future implications post pandemic.
At the fully in-person meeting of the Asembia 2021 Specialty Pharmacy Summit, held in Las Vegas, Nevada, attendees will get multiple sessions looking into the future of specialty pharmacy, as well as sessions on hot topics like telehealth and health equity.
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
In 2 sessions at the Asembia 2021 Specialty Pharmacy Summit, George Van Antwerp, MBA, managing director, Deloitte Consulting, will provide a look at the future of specialty pharmacy and health equity in pharmacy.
As deductibles for Medicare Part D beneficiaries and enrollment continue to rise, new policies and reconciliation negotiations aimed at lowering costs may hold the key to stabilizing Part D plans, according to presenters at the Academy of Managed Care Pharmacy Nexus 2021 meeting.
Two posters presented at AMCP Nexus 2021 review the high burden of social determinants of health (SDOH) on patients with serious mental illness.
During her presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting, Aimee Tharaldson, PhD, highlighted the most anticipated specialty pharmacy drugs awaiting FDA approval, including several treatments for cancer and rare diseases.
Novel financial concepts will help to ensure sustainable access to gene and cell therapies, which may help reduce disparities, said Jane F. Barlow, MD, MPH, MBA, senior advisor, FoCUS Project, MIT Center for Biomedical Innovation, and executive vice president and chief clinical officer at Real Endpoints.
There are potential ways that precision medicine could exacerbate disparities, but it should be used to guide people to the right treatments, said Nick Page, chief clinical and strategy officer, and Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, vice president of clinical programs and services, WellDyne.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
